HC Wainwright & Co. Maintains Buy on ALX Oncology Holdings, Lowers Price Target to $16
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a 'Buy' rating on ALX Oncology Holdings (NASDAQ:ALXO) but has lowered the price target from $30 to $16.

August 11, 2023 | 10:45 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target, HC Wainwright & Co. maintains a 'Buy' rating on ALX Oncology Holdings, indicating continued confidence in the company's prospects.
The lowered price target could potentially indicate a perceived decrease in ALX Oncology's future earnings potential. However, the maintained 'Buy' rating suggests that the analyst still sees value in the company's stock, which could mitigate any negative impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100